Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This real-world study will describe the demographic and clinical characteristics and mavacamten treatment of adult patients with obstructive hypertrophic cardiomyopathy who participated in the Bristol-Myers Squibb (BMS)-sponsored CAMZYOS Patient Support Program in Canada.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Adults participants treated with mavacamten | Participants with symptomatic obstructive hypertrophic cardiomyopathy (NYHA functional class II-III) who receive mavacamten as part of routine clinical care. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mavacamten | Drug | As per product label |
|
| Measure | Description | Time Frame |
|---|---|---|
| Participant demographics | Baseline | |
| Participant clinical characteristics | Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Dose regimen of mavacamten treatment | Every 3-months up to 14 months | |
| Titration patterns of mavacamten treatment | Up to 14 months | |
| Mavacamten treatment duration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
• There are no exclusion criteria.
Not provided
Not provided
Not provided
Adult participants in Canada diagnosed with hypertrophic cardiomyopathy (oHCM) receiving mavacamten treatment as part of the BMS-sponsored CAMZYOS Patient Support Program
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| St. Paul's Hospital | Vancouver | British Columbia | Canada |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42327436 | Derived | Ong K, Garceau P, Crean AM, Moeller AD, Kolman L, Corriveau S, Brellier F, Wong C, Ward MR. Early Insights on Mavacamten Usage in Canada: A Retrospective Cohort Study of the Mavacamten Patient Support Program. CJC Open. 2026 Feb 24;8(6):627-636. doi: 10.1016/j.cjco.2026.02.012. eCollection 2026 Jun. |
| Label | URL |
|---|---|
| BMS Clinical Trial Information | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002312 | Cardiomyopathy, Hypertrophic |
| ID | Term |
|---|---|
| D009202 | Cardiomyopathies |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D001020 | Aortic Stenosis, Subvalvular |
Not provided
Not provided
| ID | Term |
|---|---|
| C000605992 | MYK-461 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Up to 14 months |
| FDA Safety Alerts and Recalls | View source |
| D001024 |
| Aortic Valve Stenosis |
| D000082862 | Aortic Valve Disease |
| D006349 | Heart Valve Diseases |